Design of a randomised, double-blind, crossover, placebo-controlled trial of effects of sildenafil on cerebrovascular function in small vessel disease: Oxford haemodynamic adaptation to reduce pulsatility trial (OxHARP).
Alastair John Stewart WebbDavid WerringJesse DawsonAlex RothmanAmy LawsonKarolina WartolowskaPublished in: European stroke journal (2021)
Reduction in cerebral pulsatility and increased cerebrovascular reactivity during treatment with sildenafil would indicate potential benefit to prevent progression of SVD, suggesting a need for trials with clinical outcomes.Trial Registration OxHARP is registered with ClinicalTrials.org, NCT03855332.